Organon &

Organon & P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Organon & (OGN) as of Oct 29, 2026 is 2.74. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 2.05 — a change of 34.14% (higher).

P/CF

2.74

YoY

34.14%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Organon & is 2025 2.74 . P/CF (Price-to-Cash-Flow Ratio) of Organon & was 2024 2.05 . It decreases by 34.14% higher compared to the previous year.

The Organon & P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
0.52 USD
Jan 1, 2019
0.69 USD
Jan 1, 2020
0.88 USD
Jan 1, 2021
0.78 USD
Jan 1, 2022
2.24 USD
Jan 1, 2023
2.40 USD
Jan 1, 2024
2.05 USD
Jan 1, 2025
2.74 USD
The Organon & P/CF history
YEARP/CFYoY
2.74+34.14%
2.05-14.91%
2.40+7.38%
2.24+186.48%
0.78-11.03%
0.88+26.52%
0.69+33.25%
0.52-7.27%
0.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

P/CF (Price-to-Cash-Flow Ratio) of Organon & is 2.74 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Organon & changed from 2.05 to 2.74, representing a 34.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Organon & since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Organon & with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Organon &

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Organon &